A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Anticoagulation Therapy After Biologic Aortic Valve Replacement
Tekijät: Myllykangas Monna E, Kiviniemi Tuomas O, Gunn Jarmo M, Salomaa Veikko V, Pietilä Arto, Niiranen Teemu J, Aittokallio Jenni
Kustantaja: FRONTIERS MEDIA SA
Julkaisuvuosi: 2021
Journal: Frontiers in Cardiovascular Medicine
Tietokannassa oleva lehden nimi: FRONTIERS IN CARDIOVASCULAR MEDICINE
Lehden akronyymi: FRONT CARDIOVASC MED
Artikkelin numero: ARTN 698784
Vuosikerta: 8
Sivujen määrä: 4
ISSN: 2297-055X
eISSN: 2297-055X
DOI: https://doi.org/10.3389/fcvm.2021.698784
Verkko-osoite: https://www.frontiersin.org/articles/10.3389/fcvm.2021.698784/full
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/66685567
Objectives: Thromboembolism prophylaxis after biologic aortic valve replacement (BAVR) is recommended for 3 months postoperatively. We examined the continuation of oral anticoagulation (OAC) treatment and its effect on the long-term prognosis after BAVR.
Methods: We used nation-wide register data from 4,079 individuals who underwent BAVR. We examined the association between warfarin and the non-vitamin K antagonist oral anticoagulant use with death, stroke and major bleeding in 2010 – 2016.
Results: The risk of stroke was higher (HR 2.39, 95% CI 1.62 – 3.53, p < 0.001) and the risk of death was lower (HR 0.79, 95% CI 0.65 – 0.96, p = 0.016) in OAC-users compared to individuals without OAC. We observed no significant associations between OAC use and bleeding risk.
Conclusion: OAC use after BAVR was associated with increased risk of stroke and decreased risk of death. These observational findings warrant validation in randomized controlled trials before any clinical conclusions can be drawn.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
